uBriGene Launches uVivo Lentiviral Vector Platform to Accelerate the Development of Next-Generation In Vivo CAR-T TherapiesGERMANTOWN, MD / ACCESS Newswire / July 16, 2026 / uBriGene Biosciences, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, today announced the launch of its patented uVivo™ Lentiviral Vector (LVV) Platform. uVivo™ LVV is a proven and targeted in vivo CAR-T platform that enables safer, more efficient, and commercially scalable in vivo CAR-T therapies.
